Portal Vein Embolization in the Setting of Staged Hepatectomy with Preservation of Segment IV ± I Only for Bilobar Colorectal Liver Metastases: Safety,Efficacy, and Clinical Outcomes

Purpose

To assess frequency of adverse events, efficacy, and clinical outcomes of percutaneous portal vein embolization (PVE) in patients with bilobar colorectal liver metastases undergoing staged hepatectomy with preservation of segment IV ± I only.

The pattern of lymph node metastases in microsatellite unstable gastric cancer

Background

Microsatellite instability (MSI) is one of the new groups of molecular divisions of gastric cancer (GC). The aim of this study was to investigate the pattern of lymph node metastasis according to MSI status.

Primary tumour resection may improve survival in functional well-differentiated neuroendocrine tumours metastatic to the liver

Background

Functional well-differentiated neuroendocrine tumours (NET) with liver metastases represent a therapeutic challenge with few alternative options in guidelines. In these patients, the role of surgical resection of the primary tumour is controversial.

Screening and evaluation of the role of immune genes of brain metastasis in lung adenocarcinoma progression based on the TCGA and GEO databases

BackgroundBrain metastasis was one of the factors leading to the poor long-term prognosis of patients with lung adenocarcinoma (LUAD).MethodsThe expression levels of immune genes in LUAD and LUAD brain metastases tissues were analyzed in {"type":"entrez-geo","attrs":{"text":"GSE161116","term_id":"161116"}}GSE161116 dataset using the GEO2R, and the levels of differential immune genes in normal lung and LUAD tissues were verified. The biological functions and signaling mechanisms of the differential immune genes were explored via Gene Ontology and Kyoto Encyclopedia of Genes and Genomes analysis. Cox regression analysis was used to screen the prognostic factors of LUAD patients, and a risk model was constructed. The role of the model was checked in the development of LUAD via receiver operating characteristic analysis, gene set enrichment analysis, and Cox regression analysis.ResultsDifferentially expressed genes (DEGs) in brain metastasis were involved in the adaptive immune response, B cell differentiation, leukocyte migration, NF-kB signaling pathway, among others. The expression levels of TNFRSF11A, MS4A2, IL11, CAMP, MS4A1, and F2RL1 were independent factors affecting the poor prognosis of LUAD patients via Cox regression analysis and Akaike information criterion. In the constructed risk model, the overall survival of LUAD patients in the high-risk group was poor. The risk model was significantly related to the gender, clinical stage, T stage, lymph node metastasis, and survival status of LUAD patients. In addition, the risk model score was an independent risk factor that affected the poor prognosis of LUAD patients. TNFRSF11A, CAMP, F2RL1, IL11, MS4A1, and MS4A2 of the risk factors had diagnostic significance in LUAD brain metastasis and LUAD. The risk model participated in cytokinetic process, cell cycle, citrate cycle TCA cycle, etc. The risk model score was correlated with the levels of B cells memory, mast cells resting, macrophages M0, mast cells activated, neutrophils, eosinophils, T cells gamma delta, and immune cell markers.ConclusionsThe risk model based on the LUAD brain metastasis immune factors TNFRSF11A, MS4A2, IL11, CAMP, MS4A1, and F2RL1 was related to the diagnosis, poor prognosis, and immune infiltrating cells of LUAD patients, and is expected to provide a reference for the development of treatment strategies for LUAD patients.     

为医疗设备选择操作系统

医疗设备必须满足严格的产品质量要求,达到严格的行业标准以便通过各种认证。设备制造企业如果在产品操作系统的选择上谨慎行事,那么就可以在整个认证过程中节省时间和经费并且显著提高产品通过认证的概率。本文介绍了不同的操作系统架构,讲解了为何"微内核结构"更适合医疗设备的特点,以及该架构的操作系统如何能帮助企业满足本行业的特殊需求,通过各种认证。     

U-2OS中抑癌基因pitx1突变的鉴定及分析

目的 克隆人骨肉瘤细胞U-2OS中抑癌基因pitx1,进行测序,并检测pitx1下游基因p53的表达情况.方法 采用RT-PCR法扩增U-2OS中Pitx1基因,并进行克隆测序;采用定量PCR和western blot方法 检测pitx1下游基因p53的RNA和蛋白水平表达情况.结果 在U-2OS中抑癌基因pitx1发生突变,其下游基因p53的相对表达量显著低于pitx1野生型细胞株HOS.结论 pitx1 属于重要的抑癌基因p53及原癌基因ras的上游调控因子,在pitx1中的突变可能导致了该细胞株的恶变及化疗耐药.     

Old formula, new Rx: the journey of PHY906 as cancer adjuvant therapy

Ethnopharmacological relevance

PHY906, is a decoction of a mixture of the four herbs Scutellaria baicalensis Geori, Glycyrrhiza uralensis Fisch, Paeonia lactiflora Pall, and Ziziphus jujuba Mill. A combination of these four herbs has been in continuous use in traditional Chinese medicine for over 1800 years for treating a variety of gastrointestinal distress such as diarrhea, cramps, nausea, vomiting etc.

Aim of the study

Preclinical and clinical studies to find PHY906 enhances the therapeutic indices of a broad spectrum of anticancer agents.

Materials and methods

Using various mouse tumor xenograft and allograft models, PHY906 has been shown to enhance the chemotherapeutic efficacy of a variety of anticancer agents in various cancers. The PHY906 clinical program consists of five trials in three different types of cancers in both the United States and Taiwan. To date, approximately 150 subjects have received PHY906 in combination with chemotherapy in these five clinical studies.

Results

Preclinical studies have shown that PHY906 enhances the therapeutic indices of a broad spectrum of anticancer agents. These findings have been examined in clinical studies for colorectal, liver, and pancreatic cancers when PHY906 is used as an adjuvant to chemotherapy and the results were promising; i.e. PHY906 could reduce chemotherapy-induced toxicities and/or increase chemotherapeutic efficacy. Furthermore, PHY906 did not affect the pharmacokinetics of the chemotherapeutic agents used. Some information has been obtained regarding the mechanism of action of PHY906 in preclinical studies. A comprehensive platform, PhytomicsQC that integrates chemical and biological fingerprints together with a novel biostatistical methodology has been developed to assess the quality of different batches of PHY906.

Conclusions

Over a ten-year period, the multiplex technology “PhytomicsQC” has been used to show batch-to-batch consistency of PHY906 production. Advanced clinical trials are ongoing to demonstrate the effectiveness of PHY906 as adjuvant therapy for cancer patients undergoing chemotherapy.